Sutro Biopharma (STRO) Non-Current Assets (2017 - 2025)

Sutro Biopharma has disclosed Non-Current Assets across 9 years of filings, most recently posting $22.9 million for Q4 2025.

• Non-Current Assets for Q4 2025 came in at $22.9 million, down 47.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $115.2 million (down 37.51% YoY), and the FY2025 annual result was $22.9 million, down 47.82% from the prior year.
• Non-Current Assets came in at $22.9 million for Q4 2025 at Sutro Biopharma, down from $27.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $122.9 million in Q4 2021 to a low of $22.9 million in Q4 2025.
• The 5-year median for Non-Current Assets is $51.7 million (2023), against an average of $58.1 million.
• Across the five-year window, Non-Current Assets soared 708.24% in 2021 and plunged 56.23% in 2022, its largest moves.
• Sutro Biopharma's Non-Current Assets stood at $122.9 million in 2021, then plunged by 56.23% to $53.8 million in 2022, then fell by 8.55% to $49.2 million in 2023, then slipped by 10.77% to $43.9 million in 2024, then tumbled by 47.82% to $22.9 million in 2025.
• The last three Non-Current Assets figures came in at $22.9 million (Q4 2025), $27.5 million (Q3 2025), and $30.7 million (Q2 2025), per Business Quant data.